Hamid Mani

Stratify Genomics, Inc. operates as a cancer risk stratification company. It uses proprietary chemistry to deliver low cost next-generation sequencing to identify methods of saving lives and healthcare spend through modified screening frequency. The company was founded by A. Karim Kader and Dalaura Kader and is headquartered in San Diego, CA.

Stratify Genomics, Inc. operates as a cancer risk stratification company. It uses proprietary chemistry to deliver low cost next-generation sequencing to identify methods of saving lives and healthcare spend through modified screening frequency. The company was founded by A. Karim Kader and Dalaura Kader and is headquartered in San Diego, CA.

Stratify Genomics, Inc. operates as a cancer risk stratification company. It uses proprietary chemistry to deliver low cost next-generation sequencing to identify methods of saving lives and healthcare spend through modified screening frequency. The company was founded by A. Karim Kader and Dalaura Kader and is headquartered in San Diego, CA.

Stratify Genomics, Inc. operates as a cancer risk stratification company. It uses proprietary chemistry to deliver low cost next-generation sequencing to identify methods of saving lives and healthcare spend through modified screening frequency. The company was founded by A. Karim Kader and Dalaura Kader and is headquartered in San Diego, CA.

Stratify Genomics, Inc. operates as a cancer risk stratification company. It uses proprietary chemistry to deliver low cost next-generation sequencing to identify methods of saving lives and healthcare spend through modified screening frequency. The company was founded by A. Karim Kader and Dalaura Kader and is headquartered in San Diego, CA.